Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/9094
P465L-PPAR gamma mutation confers partial resistance to the hypolipidaemic action of fibrates
WOS ID: 000444185800003
Scopus EID: 2-s2.0-85051946983
Embase PUI: L623854757
StatisticsItem usage statistics
MetadataShow Dublin Core item record
Document typeresearch article
CitationRodriguez-Cuenca S, Carobbio S, Barceló-Coblijn G, Prieur X, Relat J, Amat R, et al. P465L-PPAR gamma mutation confers partial resistance to the hypolipidaemic action of fibrates. Diabetes Obes Metab. 2018 Oct;20(10):2339-50. Epub 2018 Jun 27.
Aims: Familial partial lipodystrophic syndrome 3 (FPLD3) is associated with mutations in the transcription factor PPAR gamma. One of these mutations, the P467L, confers a dominant negative effect. We and others have previously investigated the pathophysiology associated with this mutation using a humanized mouse model that recapitulates most of the clinical symptoms observed in patients who have been phenotyped under different experimental conditions. One of the key clinical manifestations observed, both in humans and mouse models, is the ectopic accumulation of fat in the liver. With this study we aim to dissect the molecular mechanisms that contribute to the excessive accumulation of lipids in the liver and characterize the negative effect of this PPAR gamma mutation on the activity of PPAR alpha in vivo when activated by fibrates. Material and Methods: P465L-PPAR mutant and wild-type mice were divided into 8 experimental groups, 4 different conditions per genotype. Briefly, mice were fed a chow diet or a high-fat diet (HFD 45% Kcal from fat) for a period of 28 days and treated with WY14643 or vehicle for five days before culling. At the end of the experiment, tissues and plasma were collected. We performed extensive gene expression, fatty acid composition and histological analysis in the livers. The serum collected was used to measure several metabolites and to perform basic lipoprotein profile. Results: P465L mice showed increased levels of insulin and free fatty acids (FFA) as well as increased liver steatosis. They also exhibit decreased levels of very low density lipoproteins (VLDL) when fed an HFD. We also provide evidence of impaired expression of a number of well-established PPAR alpha target genes in the P465L mutant livers. Conclusion: Our data demonstrate that P465L confers partial resistance to the hypolipidemic action of fibrates. These results show that the fatty liver phenotype observed in P465L mutant mice is not only the consequence of dysfunctional adipose tissue, but also involves defective liver metabolism. All in all, the deleterious effects of P465L-PPAR gamma mutation may be magnified by their collateral negative effect on PPAR alpha function.
Disease Models, Animal
Amino Acid Substitution
DeCSSustitución de Aminoácidos
Resistencia a Medicamentos
Modelos Animales de Enfermedad